Further analysis of the crouzon mouse: Effects of the FGFR2C342Y mutation are cranial bone-dependent

Calcified Tissue International

Volumn 92, Issue 5, 2013, Pages 451-466

  Liu, Jin ^a   Nam, Hwa Kyung ^a   Wang, Estee ^a   Hatch, Nan E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bone; Craniofacial; Craniosynostosis; Fibroblast growth factor receptor; Osteoblast

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; FGFR2 PROTEIN, MOUSE;

ACROCEPHALOSYNDACTYLY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY GROWTH; BONE DENSITY; BONE MASS; BONE MINERAL; CELL DIFFERENTIATION; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; CRANIAL SUTURE; CRANIOFACIAL SYNOSTOSIS; CROUZON SYNDROME; FACE; FACIAL BONE; FEMALE; FRONTAL BONE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; MALE; MALOCCLUSION; MICRO-COMPUTED TOMOGRAPHY; MIDFACE HYPOPLASIA; MOUSE; NASAL BONE; NONHUMAN; OCCIPITAL BONE; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; SKULL; SKULL BASE; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BONE; DISEASE MODEL; GENETICS; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; BONE AND BONES; CELL DIFFERENTIATION; CRANIOFACIAL DYSOSTOSIS; CRANIOSYNOSTOSES; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MUTATION; OSTEOBLASTS; PHENOTYPE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SKULL; TIME FACTORS;

EID: 84891550982     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-013-9701-2     Document Type: Article

References (49)

1. Renier D, Lajeunie E, Arnaud E, Marchac D (2000) Management of craniosynostoses. Childs Nerv Syst 16(10-11):645-658
2. Seruya M, Oh AK, Boyajian MJ, Posnick JC, Keating RF (2011) Treatment for delayed presentation of sagittal synostosis: Challenges pertaining to occult intracranial hypertension. J Neurosurg Pediatr 8(1):40-48
3. Morriss-Kay GM, Wilkie AO (2005) Growth of the normal skull vault and its alteration in craniosynostosis: Insights from human genetics and experimental studies. J Anat 207(5):637-653
4. Kreiborg S (1981) Craniofacial growth in plagiocephaly and Crouzon syndrome. Scand J Plast Reconstr Surg 15(3):187-197
5. Cohen MM Jr (1993) Sutural biology and the correlates of craniosynostosis. Am J Med Genet 47:581-616
6. Okajima K, Robinson LK, Hart MA, Abuelo DN, Cowan LS, Hasegawa T, Maumenee IH, Jabs EW (1999) Ocular anterior chamber dysgenesis in craniosynostosis syndromes with a fibroblast growth factor receptor 2 mutation. Am J Med Genet 85(2):160-170
7. Stavrou P, Sgouros S, Willshaw HE, Goldin JH, Hockley AD, Wake MJ (1997) Visual failure caused by raised intracranial pressure in craniosynostosis. Childs Nerv Syst 13(2):64-67
8. Abe H, Ikota T, Akino M, Kitami K, Tsuru M (1985) Functional prognosis of surgical treatment of craniosynostosis. Childs Nerv Syst 1(1):53-61
9. Shah PS, Siriwardena K, Taylor G, Steele L, Ray P, Blaser S, Chitayat D (2006) Sudden infant death in a patient with FGFR3 P250R mutation. Am J Med Genet A 140(24):2794-2796
10. Rasmussen SA, Yazdy MM, Frías JL, Honein MA (2008) Priorities for public health research on craniosynostosis: Summary and recommendations from a Centers for Disease Control and Prevention-sponsored meeting. Am J Med Genet A 146A(2): 149-158
11. Cohen MM Jr, Kreiborg S (1992) Upper and lower airway compromise in the Apert syndrome. Am J Med Genet 44(1):90-93
12. Cunningham ML, Seto ML, Ratisoontorn C, Heike CL, Hing AV (2007) Syndromic craniosynostosis: From history to hydrogen bonds. Orthod Craniofac Res 10(2):67-81
13. FlapperWJ, Anderson PJ,RobertsRM,David DJ (2009) Intellectual outcomes following protocolmanagement in Crouzon, Pfeiffer, and Muenke syndromes. J Craniofac Surg 20(4):1252-1255
14. Baird LC, Gonda D, Cohen SR, Evers LH, Lefloch N, Levy ML, Meltzer HS (2011) Craniofacial reconstruction as a treatment for elevated intracranial pressure. Childs Nerv Syst 28(3):411-418
15. Boyadjiev SA, International Craniosynostosis Consortium (2007) Genetic analysis of non-syndromic craniosynostosis. Orthod Craniofac Res 10(3):129-137
16. Wilkie AO, Byren JC, Hurst JA, Jayamohan J, Johnson D, Knight SJ, Lester T, Richards PG, Twigg SR, Wall SA (2010) Prevalence and complications of single-gene and chromosomal disorders in craniosynostosis. Pediatrics 126(2):e391-e400
17. Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, Malcolm S (1994) Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 8:98-103
18. Schell U, Hehr A, Feldman GJ, Robin NH, Zackai EH, de Die-Smulders C, Viskochil DH, Stewart JM, Wolff G, Ohashi H et al (1995) Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. Hum Mol Genet 4:323-328
19. Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD, Hayward RD, David DJ, Pulleyn LJ, Rutland P et al (1995) Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9:165-172
20. Ibrahimi OA, Zhang F, Eliseenkova AV, Linhardt RJ, Mohammadi M (2004) Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet 13:69-78
21. Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P (2004) A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci USA 101:12555-12560
22. Yin L, Du X, Li C, Xu X, Chen Z, Su N, Zhao L, Qi H, Li F, Xue J, Yang J, Jin M, Deng C, Chen L (2008) A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone 42:631-643
23. Cohen MM Jr, Kreiborg S (1992) Birth prevalence studies of the Crouzon syndrome: Comparison of direct and indirect methods. Clin Genet 41(1):12-15
24. Online Mendelian Inheritance in Man. Johns Hopkins University, Baltimore, MD. MIM number: 123500. http://omim.org/entry/123500. Accessed 22 June 2012
25. Perlyn CA, DeLeon VB, Babbs C, Govier D, Burell L, Darvann T, Kreiborg S, Morriss-Kay G (2006) The craniofacial phenotype of the Crouzon mouse: Analysis of a model for syndromic craniosynostosis using three-dimensional microCT. Cleft Palate Craniofac J 43(6):740-748
26. Flippen JH Jr (1950) Cranio-facial dysostosis of Crouzon; report of a case in which the malformation occurred in four generations. Pediatrics 5(1):90-96
27. Holmes G, Rothschild G, Roy UB, Deng C, Mansukhani A, Basilico C (2009) Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol 328:273-284
28. Zhou YX, Xu X, Chen L, Li C, Brodie SG, Deng CX (2000) A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet 9:2001-2008
29. Lomri A, Lemonnier J, Hott M, de Parseval N, Lajeunie E, Munnich A, Renier D, Marie PJ (1998) Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest 101:1310-1317
30. Fragale A, Tartaglia M, Bernardini S, Di Stasi AM, Di Rocco C, Velardi F, Teti A, Battaglia PA, Migliaccio S (1999) Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol 154:1465-1477
31. Mansukhani A, Bellosta P, Sahni M, Basilico C (2000) Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Bone Miner Res 149: 1297-1308
32. Chen L, Li D, Li C, Engel A, Deng CX (2003) A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 33:169-171
33. Wang Y, Sun M, Uhlhorn VL, Zhou X, Peter I, Martinez-Abadias N, Hill CA, Percival CJ, Richtsmeier JT, Huso DL, Jabs EW (2010) Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(?P253R) mice. BMC Dev Biol 10:22
34. Twigg SR, Healy C, Babbs C, Sharpe JA, Wood WG, Sharpe PT, Morriss-Kay GM, Wilkie AO (2009) Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome. Dev Dyn 238(2):331-342
35. Richtsmeier JT, Baxter LL, Reeves RH (2000) Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice. Dev Dyn 217(2):137-145
36. Lele S, Richtsmeier JT (2001) An invariant approach to statistical analysis of shapes. Chapman & Hall/CRC, Boca Raton
37. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468-1486
38. Hatch N, Li Y, Franceschi RT (2009) FGF2 stimulated expression of the pyrophosphate generating enzyme, PC-1, is mediated by Runx2. J Bone Miner Res 24(4):652-662
39. McCarthy TL, Centrella M, Canalis E (1988) Further biochemical and molecular characterization of primary rat parietal bone cell cultures. J Bone Miner Res 3(4):401-408
40. Harris SE, Sabatini M, Harris MA, Feng JQ, Wozney J, Mundy GR (1994) Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells. J Bone Miner Res 9(3):389-394
41. Ducy P, Karsenty G (1995) Two distinct osteoblast-specific cisacting elements control expression of a mouse osteocalcin gene. Mol Cell Biol 15(4):1858-1869
42. Marti'nez-Abadi'as N, Heuzé Y, Wang Y, Jabs EW, Aldridge K, Richtsmeier JT (2011) FGF/FGFR signaling coordinates skull development by modulating magnitude of morphological integration: Evidence from Apert syndrome mouse models. PLoS One 6(10):e26425
43. Holmes G, Basilico C (2012) Mesodermal expression of Fgfr2S252 W is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndrome. Dev Biol 368(2): 283-293
44. Li S, Quarto N, Longaker MT (2010) Activation of FGF signaling mediates proliferative and osteogenic differences between neural crest derived frontal and mesoderm parietal derived bone. PLoS One 5(11):e14033
45. Behr B, Panetta NJ, Longaker MT, Quarto N (2010) Different endogenous threshold levels of fibroblast growth factor ligands determine the healing potential of frontal and parietal bones. Bone 47(2):281-294
46. Quarto N, Behr B, Li S, Longaker MT (2009) Differential FGF ligands and FGF receptors expression pattern in frontal and parietal calvarial bones. Cells Tissues Organs 190(3):158-169
47. Iseki S, Wilkie AO, Heath JK, Ishimaru T, Eto K, Morriss-Kay GM (1997) Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2. Development 124:3375-3384
48. Iseki S, Wilkie AO, Morriss-Kay GM (1999) Fgfr1 and Fgfr2 have distinct differentiation-and proliferation-related roles in the developing mouse skull vault. Development 126:5611-5620
49. Lemonnier J, Hay E, Delannoy P, Fromigué O, Lomri A, Modrowski D, Marie PJ (2001) Increased osteoblast apoptosis in Apert craniosynostosis: Role of protein kinase C and interleukin-1. Am J Pathol 158(5):1833-1842